Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
about
Pathogenesis of human immunodeficiency virus infectionEvolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein.V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant.Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane proteinNeutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope proteinVariability of the env gene in cynomolgus macaques persistently infected with human immunodeficiency virus type 2 strain ben.The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.In vivo genetic variability of the human immunodeficiency virus type 2 V3 region.Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodiesLocation, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoproteinEfficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys.HIV-2 neutralization by intact V3-specific Fab fragments.
P2860
Q24634681-DF4E00E0-6A28-4C2B-B354-51889D4118C7Q33809419-ABCE3E1F-F019-471A-81F3-48559DB86ED5Q33935988-B9905339-FF8E-41E6-B146-737A9FB3061CQ33973817-9F3AFDFA-B154-4836-85EF-1B77F7699EACQ34290973-18F39EFC-DB8B-46B7-B8D7-7FCD7C51A6ECQ34611466-1CC6B9DF-E181-4A29-A56C-66E7491B54AEQ35665722-B2D82A01-CD20-4E65-B4DB-1EEB52CE0E7BQ35839457-EA446C0E-C121-4667-954B-E8DCB0699A9CQ35896178-78FC20BE-519D-41D6-AE3D-49005B3AF863Q36622661-E1C27522-1B50-499F-8907-ACE76F6F7006Q36632605-64899D3E-8C93-46B7-A7BB-C539C0BB02DFQ36632917-322D93E1-3B43-48A8-AD5E-37645578B7D8Q36634149-280D45CD-3C85-496E-B860-C58039C5B895Q36698091-64475C72-740A-4500-85C6-7496FCCAC742Q36699146-2B657D20-3197-474A-AAC3-EF237FDE45A9Q37284795-E589A16F-9DA2-4CA9-ABE5-B9B28C2C0299Q39875204-E83871F6-56B2-41B6-9E9E-8E65AF25D623Q41491959-7DE918DB-56FA-45FC-B328-90F23B7B2C3CQ41823383-C2EC5750-F4B4-4E39-ABB6-D138C867F43B
P2860
Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hyperimmune antisera against s ...... -dependent cytotoxic activity.
@en
Hyperimmune antisera against s ...... -dependent cytotoxic activity.
@nl
type
label
Hyperimmune antisera against s ...... -dependent cytotoxic activity.
@en
Hyperimmune antisera against s ...... -dependent cytotoxic activity.
@nl
prefLabel
Hyperimmune antisera against s ...... -dependent cytotoxic activity.
@en
Hyperimmune antisera against s ...... -dependent cytotoxic activity.
@nl
P2093
P2860
P356
P1476
Hyperimmune antisera against s ...... -dependent cytotoxic activity.
@en
P2093
Bernardi D
Björling E
Thorstensson R
P2860
P304
P356
10.1073/PNAS.88.14.6082
P407
P577
1991-07-01T00:00:00Z